A pharmacokinetic study of doxapram in patients and volunteers
- PMID: 32901
- PMCID: PMC1429614
- DOI: 10.1111/j.1365-2125.1979.tb00901.x
A pharmacokinetic study of doxapram in patients and volunteers
Abstract
1. Following intravenous bolus injections or brief infusions in healthy volunteers, plasma concentrations of doxapram declined in a multi-exponential fashion. The mean half-life from 4-12 h was 3.4 h (range 2.4-4.1h), the mean apparent volume of distribution was 1.5 1 kg-1 and the whole body clearance was 370 ml min-1. 2. Enteric-coated capsules of doxapram base were absorbed rapidly after an initial delay, and the systemic availability was about 60%. 3. Doxapram is extensively metabolized and less than 5% of an i.v. dose was excreted unchanged in the urine in 24 h. A metabolite (AHR 5955) was present in plasma in amounts comparable to the parent compound and had a similar half-life. 4. The disposition of doxapram appears to be similar in healthy volunteers and patients with respiratory failure. 5. The previously held belief that plasma concentrations fall rapidly when an infusion is stopped is only true following short duration infusions. The pharmacokinetic properties of doxapram are such that steady-state plasma concentrations will not be achieved for many hours with the recommended constant rate infusion régime.
Similar articles
-
The disposition of intravenous doxapram in man.Eur J Clin Pharmacol. 1979;16(6):411-6. doi: 10.1007/BF00568202. Eur J Clin Pharmacol. 1979. PMID: 527638
-
Pharmacokinetics and metabolism of intravenous doxapram in horses.Equine Vet J Suppl. 1992 Feb;(11):45-51. doi: 10.1111/j.2042-3306.1992.tb04772.x. Equine Vet J Suppl. 1992. PMID: 9109960
-
Doxapram dosage regimen in apnea of prematurity based on pharmacokinetic data.Dev Pharmacol Ther. 1988;11(5):253-7. doi: 10.1159/000457699. Dev Pharmacol Ther. 1988. PMID: 3191816
-
Clevidipine: a review of its use in the management of acute hypertension.Am J Cardiovasc Drugs. 2009;9(2):117-34. doi: 10.2165/00129784-200909020-00006. Am J Cardiovasc Drugs. 2009. PMID: 19331440 Review.
-
Clinical pharmacokinetics of amiodarone.Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002. Clin Pharmacokinet. 1984. PMID: 6370540 Review.
Cited by
-
Simultaneous Quantification and Pharmacokinetic Characterization of Doxapram and 2-Ketodoxapram in Porcine Plasma and Brain Tissue.Pharmaceutics. 2022 Mar 31;14(4):762. doi: 10.3390/pharmaceutics14040762. Pharmaceutics. 2022. PMID: 35456597 Free PMC article.
-
The bioavailability and maturing clearance of doxapram in preterm infants.Pediatr Res. 2021 Apr;89(5):1268-1277. doi: 10.1038/s41390-020-1037-9. Epub 2020 Jul 22. Pediatr Res. 2021. PMID: 32698193
-
A new look at the respiratory stimulant doxapram.CNS Drug Rev. 2006 Fall-Winter;12(3-4):236-49. doi: 10.1111/j.1527-3458.2006.00236.x. CNS Drug Rev. 2006. PMID: 17227289 Free PMC article. Review.
-
Normal pharmacokinetics of doxapramin in a patient with renal failure and hypothyroidism.Br J Clin Pharmacol. 1981 Mar;11(3):305-7. doi: 10.1111/j.1365-2125.1981.tb00539.x. Br J Clin Pharmacol. 1981. PMID: 7213532 Free PMC article. No abstract available.
-
Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea.Eur J Pediatr. 2015 Apr;174(4):509-18. doi: 10.1007/s00431-014-2416-1. Epub 2014 Sep 25. Eur J Pediatr. 2015. PMID: 25248340 Clinical Trial.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous